• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    MoonLake Immunotherapeutics filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    9/29/25 7:15:53 AM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MLTX alert in real time by email
    false 0001821586 0001821586 2025-09-29 2025-09-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

     

    FORM 8-K

     

    CURRENT REPORT

     

    PURSUANT TO SECTION 13 or 15(d) of the

    SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported): September 29, 2025

     

    MOONLAKE IMMUNOTHERAPEUTICS

    (Exact Name of Registrant as Specified in Its Charter)

     

    Cayman Islands   001-39630   98-1711963

    (State or Other Jurisdiction
    of Incorporation)

     

    (Commission File Number)

     

    (IRS Employer
    Identification No.)

     

    Dorfstrasse 29

    6300 Zug

    Switzerland

    (Address of Principal Executive Offices and Zip Code)

     

    41 415108022

    (Registrant’s Telephone Number, Including Area Code)

     

    N/A

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Class A ordinary share, par value $0.0001 per share   MLTX   The Nasdaq Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 8.01. Other Events.

     

    On September 28, 2025, MoonLake Immunotherapeutics (the “Company”) issued a press release announcing the week 16 results of the Phase 3 VELA-1 and VELA-2 trials of its registrational global program in patients with moderate-to-severe hidradenitis suppurativa. The Company will host a webcast today, Monday, September 29, 2025 at 8:00 am, Eastern Time, to discuss the data results.

     

    A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits. The following exhibit is being filed herewith:

     

    Exhibit
    Number
      Exhibit Title or Description
    99.1   Press Release, dated September 28, 2025
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

    1

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      MOONLAKE IMMUNOTHERAPEUTICS
       
    Date: September 29, 2025 By: /s/ Matthias Bodenstedt
      Name: Matthias Bodenstedt
      Title: Chief Financial Officer

     

    2

     

    Get the next $MLTX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MLTX

    DatePrice TargetRatingAnalyst
    9/30/2025$2.00Outperform → Underperform
    Wolfe Research
    9/30/2025$5.00Buy → Neutral
    Citigroup
    9/29/2025$8.00Buy → Hold
    Jefferies
    9/29/2025Buy → Neutral
    BTIG Research
    9/29/2025$10.00Outperform → Sector Perform
    RBC Capital Mkts
    9/29/2025$13.00Buy → Hold
    Stifel
    7/28/2025$65.00Neutral
    Rothschild & Co Redburn
    5/19/2025$61.00Peer Perform → Outperform
    Wolfe Research
    More analyst ratings

    $MLTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chen Bihua bought $3,524,297 worth of Class A Ordinary Shares (58,839 units at $59.90) (SEC Form 4)

    4 - MoonLake Immunotherapeutics (0001821586) (Issuer)

    10/10/23 4:00:43 PM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chen Bihua bought $16,800,343 worth of Class A Ordinary Shares (293,212 units at $57.30) (SEC Form 4)

    4 - MoonLake Immunotherapeutics (0001821586) (Issuer)

    10/4/23 5:52:22 PM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MLTX
    SEC Filings

    View All

    MoonLake Immunotherapeutics filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - MoonLake Immunotherapeutics (0001821586) (Filer)

    9/29/25 7:15:53 AM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by MoonLake Immunotherapeutics

    SCHEDULE 13G - MoonLake Immunotherapeutics (0001821586) (Subject)

    8/14/25 6:57:23 AM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by MoonLake Immunotherapeutics

    SCHEDULE 13G/A - MoonLake Immunotherapeutics (0001821586) (Subject)

    8/6/25 12:06:01 PM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MLTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MoonLake Immunotherapeutics reports on week 16 results of the VELA Phase 3 hidradenitis suppurativa program with the Nanobody® sonelokimab

    VELA-1 and VELA-2 are two identical trials to evaluate the efficacy and safety of sonelokimab in adult participants with moderate to severe hidradenitis suppurativa (HS) and the first Phase 3 program using the higher clinical response level of HS Clinical Response (HiSCR) 75 as primary endpoint at week 16Data was analyzed, as per protocol and in accordance with regulatory agency feedback, using a composite strategy as the primary analysis and a treatment policy strategy to test the robustness of the results: difference between the two methods relates to the statistical handling of intercurrent eventsIn the combined VELA program, patients treated with sonelokimab experienced a clinically

    9/28/25 12:04:41 PM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update

    Phase 3 VELA program in hidradenitis suppurativa (HS) on track for an expected primary endpoint readout around September 2025 and an expected submission of a Biologic License Application (BLA) in the United States in mid-2026Other clinical trials of sonelokimab in palmoplantar pustulosis (PPP), axial spondyloarthritis (axSpA), psoriatic arthritis (PsA) and adolescent HS progressing well and expected to support a catalyst-rich roadmap over the next 12 monthsEnded the second quarter with $425.1 million in cash, cash equivalents and short-term marketable debt securities with up to an additional $425 million in non-dilutive funds remaining accessible through previously announced debt-facility Z

    8/5/25 7:00:00 AM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update

    MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update Continued to make significant progress with the development of the Nanobody® sonelokimab across portfolio of indications, including Phase 3 studies in hidradenitis suppurativa (HS), psoriatic Arthritis (PsA) and adolescent HS, as well as Phase 2 studies in palmoplantar pustulosis (PPP) and axial spondyloarthritis (axSpA)Announced completion of enrollment of patients in the Phase 3 program in HS (the VELA program) and disclosed baseline characteristics, replicating the Phase 2 MIRA trialPresented an interim readout of the Phase 2 LEDA study in PPP, highlighting the potential of sonelokimab

    5/12/25 4:00:00 PM ET
    $HTGC
    $MLTX
    Investment Managers
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MLTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    MoonLake Immunotherapeutics downgraded by Wolfe Research with a new price target

    Wolfe Research downgraded MoonLake Immunotherapeutics from Outperform to Underperform and set a new price target of $2.00

    9/30/25 8:33:10 AM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MoonLake Immunotherapeutics downgraded by Citigroup with a new price target

    Citigroup downgraded MoonLake Immunotherapeutics from Buy to Neutral and set a new price target of $5.00

    9/30/25 8:32:59 AM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MoonLake Immunotherapeutics downgraded by Jefferies with a new price target

    Jefferies downgraded MoonLake Immunotherapeutics from Buy to Hold and set a new price target of $8.00

    9/29/25 2:01:19 PM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MLTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Scientific Officer Reich Kristian converted options into 48,978 units of Class A ordinary shares and returned 48,978 units of Class C ordinary shares to the company, decreasing direct ownership by 77% to 35,389 units (SEC Form 4)

    4 - MoonLake Immunotherapeutics (0001821586) (Issuer)

    9/4/25 4:01:13 PM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Moukheibir Catherine converted options into 23,500 units of Class A ordinary shares and sold $1,146,565 worth of Class A ordinary shares (23,500 units at $48.79) (SEC Form 4)

    4 - MoonLake Immunotherapeutics (0001821586) (Issuer)

    7/7/25 4:03:16 PM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Bvf Partners L P/Il

    4 - MoonLake Immunotherapeutics (0001821586) (Issuer)

    6/9/25 7:16:08 PM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MLTX
    Financials

    Live finance-specific insights

    View All

    MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update

    Phase 3 VELA program in hidradenitis suppurativa (HS) on track for an expected primary endpoint readout around September 2025 and an expected submission of a Biologic License Application (BLA) in the United States in mid-2026Other clinical trials of sonelokimab in palmoplantar pustulosis (PPP), axial spondyloarthritis (axSpA), psoriatic arthritis (PsA) and adolescent HS progressing well and expected to support a catalyst-rich roadmap over the next 12 monthsEnded the second quarter with $425.1 million in cash, cash equivalents and short-term marketable debt securities with up to an additional $425 million in non-dilutive funds remaining accessible through previously announced debt-facility Z

    8/5/25 7:00:00 AM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update

    MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update Continued to make significant progress with the development of the Nanobody® sonelokimab across portfolio of indications, including Phase 3 studies in hidradenitis suppurativa (HS), psoriatic Arthritis (PsA) and adolescent HS, as well as Phase 2 studies in palmoplantar pustulosis (PPP) and axial spondyloarthritis (axSpA)Announced completion of enrollment of patients in the Phase 3 program in HS (the VELA program) and disclosed baseline characteristics, replicating the Phase 2 MIRA trialPresented an interim readout of the Phase 2 LEDA study in PPP, highlighting the potential of sonelokimab

    5/12/25 4:00:00 PM ET
    $HTGC
    $MLTX
    Investment Managers
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update

    Initiated the Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (HS) and the Phase 3 IZAR program in patients with active psoriatic arthritis (PsA) following positive FDA and EMA regulatory feedback, continuing to support a potential best-in-class profile across two key indicationsInitiated three new trials in the beginning of 2025 with the Nanobody® sonelokimab: Phase 3 VELA-TEEN trial in adolescent hidradenitis suppurativa (HS), Phase 2 LEDA trial in palmoplantar pustulosis (PPP) and Phase 2 S-OLARIS trial in axial spondyloarthritis (axSpA)Signed a three-year technology partnership with Komodo Health to advance research on inflam

    2/26/25 7:00:00 AM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MLTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by MoonLake Immunotherapeutics

    SC 13G/A - MoonLake Immunotherapeutics (0001821586) (Subject)

    11/12/24 10:32:13 AM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by MoonLake Immunotherapeutics

    SC 13D/A - MoonLake Immunotherapeutics (0001821586) (Subject)

    10/8/24 6:48:48 PM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by MoonLake Immunotherapeutics (Amendment)

    SC 13D/A - MoonLake Immunotherapeutics (0001821586) (Subject)

    3/5/24 4:59:16 PM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care